{"id":"W2599153150","doi":"10.1200/jco.2009.27.15_suppl.8537","title":"PX-171–004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Bortezomib; Multiple myeloma; Clinical endpoint; Internal medicine; Phases of clinical research; Proteasome inhibitor; Adverse effect; Gastroenterology; Oncology; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003722524,0.0008743327,0.001774181,0.0004135469,0.0002664062,0.0008684827,0.0008356825,0.00100139,0.001812153],"category_scores_gemma":[0.001134611,0.0003737379,0.000778557,0.0005163901,0.0004338707,0.0005527107,0.0002606917,0.001874994,0.000523461],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007373664,"about_ca_system_score_gemma":0.0009386163,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007588642,"about_ca_topic_score_gemma":0.001972055,"domain_scores_codex":[0.9994223,0.0003148033,0.00004558188,0.0000570029,0.00009998903,0.00006037184],"domain_scores_gemma":[0.9992762,0.0002292301,0.0001743304,0.00003502758,0.00009012704,0.0001950853],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1323007,0.01543527,0.03930609,0.002889226,0.00219854,0.0007768589,0.0005065295,0.002496728,0.06626997,0.0006239928,0.0195526,0.7176435],"study_design_scores_gemma":[0.3829717,0.3214052,0.1943568,0.0005237715,0.004267632,0.002236211,0.0002241223,0.005004702,0.01154934,0.0006176505,0.07671636,0.0001264583],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9055432,0.07669239,0.001564221,0.005219406,0.0003060029,0.002126331,0.00213552,0.0002739758,0.00613892],"genre_scores_gemma":[0.9456917,0.03321068,0.003498695,0.006550455,0.0009571913,0.001490058,0.005803724,0.00006217281,0.002735134],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003722524,"threshold_uncertainty_score":0.01968682,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08971307137979027,"score_gpt":0.4865627822123976,"score_spread":0.3968497108326073,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}